Colossal is currently working on several high-profile species:
In October 2024, the company launched the Colossal Foundation , a non-profit dedicated to applying these technologies to today's endangered species. They are currently working on a vaccine for a deadly elephant virus (EEHV) and biobanking the "top 100" most imperiled species to ensure their genetic survival. Colossal
: Partnering with the University of Melbourne, they have achieved over 99.9% accuracy in reconstructing the thylacine genome. The Technology "Toolkit" The Technology "Toolkit" : Their spin-off, Form Bio
: Their spin-off, Form Bio , uses AI to manage the massive datasets required for genomic assembly. The Colossal Foundation Rather than simple "cloning," Colossal uses a "de-extinction
: Working with the Mauritian Wildlife Foundation, they plan to return a proxy of the dodo to Mauritius within five to seven years.
: The company aims to produce mammoth-like Asian elephant embryos by 2026, with the first calves expected by 2028.
Rather than simple "cloning," Colossal uses a "de-extinction toolkit" to edit the DNA of a living relative to match an extinct ancestor.